The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A revised RTOG recursive partitioning analysis (RPA) model for glioblastoma based upon multiplatform biomarker profiles.
Arnab Chakravarti
No relevant relationships to disclose
Meihua Wang
No relevant relationships to disclose
Kenneth D. Aldape
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech
Research Funding - AstraZeneca
Erik P. Sulman
Honoraria - Merck
Markus Bredel
No relevant relationships to disclose
Anthony M. Magliocco
No relevant relationships to disclose
Alexander C. Klimowicz
No relevant relationships to disclose
Monika Hegi
Consultant or Advisory Role - MDxHealth; MSD
Research Funding - MDxHealth
Roger Stupp
Consultant or Advisory Role - Celldex; Merck; Merck Serono
Mark R. Gilbert
Consultant or Advisory Role - Genentech; Merck
Honoraria - Genentech; Merck
Research Funding - Genentech; Merck
Walter J. Curran
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Abbott Laboratories
Maria Werner-Wasik
No relevant relationships to disclose
Anita Mahajan
No relevant relationships to disclose
Christopher J. Schultz
No relevant relationships to disclose
Minesh P. Mehta
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Elekta; Merck; Novartis; Quark; Tomotherapy; US Oncology; Vertex
Stock Ownership - Accuray; Colby; Pharmacyclics; ProCertus; Stemina